Unknown

Dataset Information

0

Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.


ABSTRACT: Triple-negative breast cancer (TNBC) is a special subtype of breast cancer in which several common diagnostic biomarkers are lost. Due to the loss of expression of receptors, treatment options for TNBC are limited. Therefore, finding safe and effective treatments for patients with TNBC is a major objective for clinicians. Previous studies suggested that cytokine-induced killer (CIK) cells may be beneficial for patients with a variety of tumor types. However, CIK therapy is not effective for all patients. In this study, we found that focal adhesion kinase (FAK), a non-receptor protein tyrosine kinase that regulates several cellular functions in different cells, has the potential to regulate tumor cells sensitized to CIK cells. Knockdown of FAK expression in TNBC cells or the treatment of TNBC cells with a FAK inhibitor followed by coculture with CIK cells increases death of TNBC cells, suggesting that FAK plays important roles in sensitizing tumor cells to CIK cells. This phenomenon could be regulated by a FAK-programmed death-ligand 1 (PD-L1)-related mechanism. Overall, our findings provide new insights into the cytotoxic effect of CIK cell therapy in TNBC treatment, and show that CIK cell therapy combined with FAK inhibitors may be a novel therapeutic strategy for patients with TNBC.

SUBMITTER: Pan MR 

PROVIDER: S-EPMC7017032 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer.

Pan Mei-Ren MR   Wu Cheng-Che CC   Kan Jung-Yu JY   Li Qiao-Lin QL   Chang Shu-Jyuan SJ   Wu Chun-Chieh CC   Li Chung-Liang CL   Ou-Yang Fu F   Hou Ming-Feng MF   Yip Hon-Kan HK   Luo Chi-Wen CW  

Cancers 20191230 1


Triple-negative breast cancer (TNBC) is a special subtype of breast cancer in which several common diagnostic biomarkers are lost. Due to the loss of expression of receptors, treatment options for TNBC are limited. Therefore, finding safe and effective treatments for patients with TNBC is a major objective for clinicians. Previous studies suggested that cytokine-induced killer (CIK) cells may be beneficial for patients with a variety of tumor types. However, CIK therapy is not effective for all  ...[more]

Similar Datasets

| S-EPMC4501353 | biostudies-literature
| S-EPMC10054905 | biostudies-literature
| S-EPMC3918886 | biostudies-literature
| S-EPMC7222372 | biostudies-literature
| S-EPMC10528299 | biostudies-literature
| S-EPMC6352244 | biostudies-literature
| S-EPMC11836529 | biostudies-literature
2023-05-01 | GSE201760 | GEO
2025-07-12 | GSE207977 | GEO
| S-EPMC7965737 | biostudies-literature